Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma

Abstract

Recombinant human activated protein C (rhAPC) also known as drotrecogin alfa (activated) has known antithrombotic, anti-inflammatory, and profibrinolytic properties in severe sepsis. Treatment with rhAPC (Xigris^®) has been shown to reduce mortality in patients with severe sepsis. The lack of any trials of rhAPC in trauma patients means that a definitive recommendation regarding its use in the polytraumatised patient, in whom severe head trauma or other contraindications for the use of rhAPC have been excluded remains controversial at present. This article describes the current evidence of its efficacy and safety in severe sepsis with relation to surgery and trauma.

Keywords::

• coagulopathy
• complication
• drotrecogin alpha (activated)
• mortality
• recombinant human activated protein C (rhAPC)
• sepsis
• trauma
• Xigris^®

View correction statement:

Erratum